Somatostatin analog

DRUG5 trials

Conditions

Carcinoid TumorsGastroenteropancreatic Neuroendocrine TumorNeuroendocrine NeoplasmNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine TumorsNeuroendocrine Tumors (NET) Health Related Qualito of Life (HRQoL)Pancreatic Diseases

Phase 2

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

CompletedNCT02795858

Dana-Farber Cancer InstituteCarcinoid Tumors

Start: 2016-06-14End: 2023-12-31Updated: 2025-02-19

Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics

SuspendedNCT04329039

Mayo ClinicPancreatic Diseases

Start: 2020-11-17End: 2027-05-06Updated: 2026-04-03

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

RecruitingNCT06855095

The Netherlands Cancer InstituteNeuroendocrine Neoplasm, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2 +1

Start: 2024-06-25End: 2027-03-01Target: 39Updated: 2025-03-03

Phase 4

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

RecruitingNCT05701241

University Hospital, AntwerpGastroenteropancreatic Neuroendocrine Tumor

Start: 2023-06-28End: 2034-04-30Target: 270Updated: 2024-06-14

Unknown Phase

Fatigue and Quality of Life in Patients With Neuroendocrine Neoplasia

NCT04557137

University of AarhusNeuroendocrine Tumors (NET) Health Related Qualito of Life (HRQoL)

Start: 2020-09-01End: 2023-01-01Target: 100Updated: 2020-09-21

Related Papers

Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol

BMJ Open2025-07-01

A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors